{
  "id": 17952645,
  "title": "US approves generic version of world’s only twice-a-year HIV prevention shot",
  "url": "https://urgent.news/2026/11/03/us-approves-generic-version-of-worlds-only-twice-a-year-hiv",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-03T11:10:45.000Z",
  "source": {
    "name": "GBC Ghana",
    "slug": "gbc-ghana",
    "url": "https://www.gbcghanaonline.com/world/us-approves-generic-version-of-worlds-only-twice-a-year-hiv-prevention-shot/2026/"
  },
  "original_language": "en",
  "account": "The US Food and Drug Administration has authorized a generic version of the world's only twice-annual HIV prevention injection, lenacapavir. This breakthrough aims to swiftly and affordably deliver the drug to 120 low- and middle-income countries. The injectable medication, costing $40 per patient annually, provides greater convenience than daily oral pills while showing nearly complete prevention of new HIV infections among high-risk individuals. Global health leaders believe this will significantly reduce HIV transmission rates, AIDS diagnoses, and mortality. Currently, 41 million people worldwide live with HIV, and 570,000 die from HIV-related causes annually. The generic version will be distributed outside the US, where the brand-name Yeztugo, produced by Gilead Sciences, remains under patent with a hefty price tag of $28,218 per year. Six generic manufacturers secured royalty-free licensing agreements with Gilead to produce and distribute lenacapavir in sub-Saharan Africa, Asia, and Latin America. While the regulatory approval is a major milestone, securing funding for widespread distribution and reaching millions of people in need remains the next critical step.",
  "summary": "By: Nana Karikari, Senior Global Affairs Correspondent The United States Food and Drug Administration has granted authorization for a generic variant of the world’s sole bi-annual HIV prevention injection. This regulatory action represents a major breakthrough toward delivering the drug rapidly and affordably to 120 low- and middle-income nations. The announcement was delivered on Monday […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 7,
    "also_reported_by": [
      {
        "outlet": "Science Magazine",
        "title": "U.S. approval of cheap, generic HIV prevention shot may boost global rollout",
        "url": "https://urgent.news/2026/11/02/u-s-approval-of-cheap-generic-hiv-prevention-shot-may-boost-global",
        "published": "2026-11-02T05:25:45.000Z"
      },
      {
        "outlet": "IOL",
        "title": "Generic lenacapavir HIV prevention shot wins US FDA approval",
        "url": "https://urgent.news/2026/11/02/generic-lenacapavir-hiv-prevention-shot-wins-us-fda-approval",
        "published": "2026-11-02T14:48:00.000Z"
      },
      {
        "outlet": "STAT News",
        "title": "STAT+: FDA OKs generic HIV prevention shot, widening access for lower-income countries",
        "url": "https://urgent.news/2026/11/02/stat-fda-oks-generic-hiv-prevention-shot-widening-access-for-lower",
        "published": "2026-11-02T16:13:46.000Z"
      },
      {
        "outlet": "Capital FM Kenya",
        "title": "Generic HIV prevention injection moves closer to 120 countries after FDA approval",
        "url": "https://urgent.news/2026/11/02/generic-hiv-prevention-injection-moves-closer-to-120-countries-after",
        "published": "2026-11-02T16:17:26.000Z"
      },
      {
        "outlet": "Medical Xpress",
        "title": "US approves cheap generic of breakthrough HIV shot for poorer countries",
        "url": "https://urgent.news/2026/11/02/us-approves-cheap-generic-of-breakthrough-hiv-shot-for-poorer",
        "published": "2026-11-02T18:55:27.000Z"
      },
      {
        "outlet": "AllAfrica Health",
        "title": "Africa: Generic HIV Prevention Injection Moves Closer to 120 Countries After FDA Approval",
        "url": "https://urgent.news/2026/11/03/africa-generic-hiv-prevention-injection-moves-closer-to-120-countries",
        "published": "2026-11-03T05:22:49.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}